+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hospital Acquired Infection Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • May 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309895
The global market for Hospital Acquired Infection Treatment is estimated at US$33.9 Billion in 2023 and is projected to reach US$40.9 Billion by 2030, growing at a CAGR of 2.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Urinary Tract Infections Treatment segment, which is expected to reach US$28.6 Billion by 2030 with a CAGR of a 2.9%. The Ventilator-Associated Pneumonia Treatment segment is also set to grow at 2.1% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $10.1 Billion in 2023, and China, forecasted to grow at an impressive 2.5% CAGR to reach $7.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Hospital Acquired Infection Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hospital Acquired Infection Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Hospital Acquired Infection Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Laboratories, Inc., Aridis Pharmaceuticals, Inc., Astellas Pharma, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 42 Featured):

  • Abbott Laboratories, Inc.
  • Aridis Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cepheid, Inc.
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Pfizer, Inc.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Hospital Acquired Infection Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Hospital Acquired Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Hospital Acquired Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Urinary Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Ventilator-Associated Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Ventilator-Associated Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 9: World 16-Year Perspective for Ventilator-Associated Pneumonia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Bloodstream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Bloodstream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 12: World 16-Year Perspective for Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Surgical Site Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Surgical Site Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 15: World 16-Year Perspective for Surgical Site Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Other Infection Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Other Infection Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 18: World 16-Year Perspective for Other Infection Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Antibacterial Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Antibacterial Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 21: World 16-Year Perspective for Antibacterial Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 23: World Historic Review for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 24: World 16-Year Perspective for Antiviral Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Antifungal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 26: World Historic Review for Antifungal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 27: World 16-Year Perspective for Antifungal Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 28: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 29: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 30: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 31: World Hospital Acquired Infection Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 32: USA Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 35: USA Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: USA Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: USA 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Canada 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
JAPAN
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Japan 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
CHINA
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 50: China Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: China Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: China 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 53: China Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: China Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: China 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
EUROPE
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 56: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Hospital Acquired Infection Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Europe 16-Year Perspective for Hospital Acquired Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Europe 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 62: Europe Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Europe 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
FRANCE
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 65: France Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: France Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: France 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 68: France Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: France Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: France 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
GERMANY
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 71: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Germany 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 74: Germany Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: Germany Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: Germany 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
ITALY
  • Table 77: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: Italy 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 80: Italy Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Italy Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: Italy 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 83: UK Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: UK Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: UK 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 86: UK Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: UK Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: UK 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of Europe 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of Europe 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Hospital Acquired Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Hospital Acquired Infection Treatment by Infection Type - Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Asia-Pacific 16-Year Perspective for Hospital Acquired Infection Treatment by Infection Type - Percentage Breakdown of Value Sales for Urinary Tract Infections, Ventilator-Associated Pneumonia, Bloodstream Infections, Surgical Site Infections and Other Infection Types for the Years 2014, 2024 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Hospital Acquired Infection Treatment by Treatment - Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Hospital Acquired Infection Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment and Other Treatments for the Years 2014, 2024 & 2030
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories, Inc.
  • Aridis Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cepheid, Inc.
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Pfizer, Inc.

Table Information